Braveheart Bio, a clinical-stage biotechnology company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, today announced the ...
Siren Biotechnology today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application submitted by the University of California, San Francisco ...
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
Tivic Health Systems is developing immune‑modulating therapies for conditions, such as radiation exposure, while expanding ...
Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement ...
This biotech innovator in rare disease therapies reported significant insider selling amid a year of robust stock performance ...
LENA Platform's four LDT products detect leukemia up to 41 months before symptoms — now live at alercell.com Alercell ...
OG Acquisition 2 Corp. (“OG” or the “Company”) is pleased to provide an update on its previously announced business ...
Union Minister of State (Independent Charge) for Science & Technology, Earth Sciences, and MoS PMO, Personnel, Public ...
STEMart announces the launch of Chromatography Columns to meet the rigorous demands of modern chemical analysis and ...
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results